WO2026022712 - CEREBLON LIGASE MODULATOR AND BCMA NK CELL ENGAGER COMBINATION THERAPY
National phase entry is expected:
Publication Number
WO/2026/022712
Publication Date
29.01.2026
International Application No.
PCT/IB2025/057431
International Filing Date
23.07.2025
Title **
[English]
CEREBLON LIGASE MODULATOR AND BCMA NK CELL ENGAGER COMBINATION THERAPY
[French]
MODULATEUR DE LIGASE CÉRÉBLON ET POLYTHÉRAPIE D'ACTIVATION DE CELLULES NK BCMA
Applicants **
SANOFI
Inventors
CHIRON, Marielle
VAN DE VELDE, Helgi
VIRONE-ODDOS, Angela
DESJONQUERES, Alexandre
Priority Data
24306234.6
23.07.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4772 | |
| EPO | Filing, Examination, Granting | 79036 | |
| Japan | Filing, Examination, Granting | 4470 | |
| South Korea | Filing, Examination, Granting | 6787 | |
| USA | Filing, Examination, Granting | 19190 |
Total:
114,255
Contact Us
Abstract[English]
The present disclosure relates to a method of treating cancer (e.g., multiple myeloma) with the combination of i) a multifunctional binding protein comprising a first and a second antigen binding domains (ABDs), wherein the first ABD binds specifically to human BCMA and the second ABD binds specifically to human NKp46; and ii) a cereblon modulating agent.[French]
La présente divulgation concerne une méthode de traitement du cancer (par exemple, le myélome multiple) avec la combinaison de i) une protéine de liaison multifonctionnelle comprenant un premier et un second domaine de liaison à l'antigène (ABD), le premier ABD se liant de manière spécifique au BCMA humain et le second ABD se liant de manière spécifique au NKp46 humain ; et ii) un agent de modulation de céréblon.